[go: up one dir, main page]

US7332514B2 - Dibenzylamine compound and medicinal use thereof - Google Patents

Dibenzylamine compound and medicinal use thereof Download PDF

Info

Publication number
US7332514B2
US7332514B2 US10/503,185 US50318504A US7332514B2 US 7332514 B2 US7332514 B2 US 7332514B2 US 50318504 A US50318504 A US 50318504A US 7332514 B2 US7332514 B2 US 7332514B2
Authority
US
United States
Prior art keywords
methyl
ethylamino
amino
trifluoromethyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/503,185
Other languages
English (en)
Other versions
US20050059810A1 (en
Inventor
Kimiya Maeda
Hironobu Nagamori
Hiroshi Nakamura
Hisashi Shinkai
Yasunori Suzuki
Daisuke Takahashi
Toshio Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Assigned to JAPAN TOBACCO INC. reassignment JAPAN TOBACCO INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAEDA, KIMIYA, SUZUKI, YASUNORI, NAGAMORI, HIRONOBU, NAKAMURA, HIROSHI, SHINKAI, HISASHI, TAKAHASHI, DAISUKE, TANIGUCHI, TOSHIO
Publication of US20050059810A1 publication Critical patent/US20050059810A1/en
Priority to US11/939,359 priority Critical patent/US7807701B2/en
Application granted granted Critical
Publication of US7332514B2 publication Critical patent/US7332514B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the present invention relates to a novel CETP activity inhibitor, particularly a therapeutic agent or a prophylactic agent of arteriosclerosis or hyperlipidemia.
  • CETP cholesterol ester transfer protein
  • CETP is produced in the organs such as liver, spleen, adrenal gland, adipose tissue, small intestine, kidney, skeletal muscle, heart muscle and the like, and produced in cells of the cell types of human monocyte-derived macrophage, B lymphocyte, fat cell, small intestinal epithelial cell, CaCo2 cell, hepatocyte (exemplified by human liver cancer cell-derived cell line, HepG2 cells) and the like.
  • hepatocyte exemplified by human liver cancer cell-derived cell line, HepG2 cells
  • it is present in cerebrospinal fluid and semen, and its presence has been confirmed in culture media of human neuroblastoma and neuroglioma cells, choroid plexus of sheep and the like.
  • CETP is involved in the metabolism of any lipoprotein in living organisms, and has a major role in the reverse cholesterol transfer system. Namely, CETP has drawn attention as a mechanism for preventing accumulation of cholesterol in peripheral cells and preventing arteriosclerosis.
  • HDL high-density lipoprotein
  • a number of epidemiological researches have shown that a decrease in CE (cholesteryl ester) of HDL in blood is one of the risk factors of coronary artery diseases.
  • CETP activity varies depending on the animal species, wherein arteriosclerosis due to cholesterol-loading is hardly induced in animals with lower activity, and in reverse, easily induced in animals with higher activity, and that hyper-HDL-emia and hypo-LDL (low density lipoprotein)-emia are induced in the case of CETP deficiency, thus rendering the development of arteriosclerosis difficult, which in turn led to the recognition of the significance of blood HDL, as well as significance of CETP that mediates transfer of CE in HDL into blood LDL.
  • arteriosclerosis due to cholesterol-loading is hardly induced in animals with lower activity, and in reverse, easily induced in animals with higher activity, and that hyper-HDL-emia and hypo-LDL (low density lipoprotein)-emia are induced in the case of CETP deficiency, thus rendering the development of arteriosclerosis difficult, which in turn led to the recognition of the significance of blood HDL, as well as significance of CETP that mediates transfer of CE in HDL into blood LDL.
  • VLDL very low density lipoprotein
  • LPL lipoprotein lipase
  • HTGL hepatic triglyceride lipase
  • IDL intermediate density lipoprotein
  • FC accumulated in the peripheral tissues is drawn by HDL, further esterified on HDL by the action of LCAT (lecithin-cholesterol acyltransferase) to form CE, and transferred to the hydrophobic core part of HDL, whereby HDL matures into spheric HDL particles.
  • CE in HDL is transferred by CETP present in blood to apoB-containing lipoproteins such as VLDL, IDL, LDL and the like, and in return, TG is transferred to HDL at a molar ratio of 1:1.
  • CE transferred to apoB-containing lipoprotein is taken up by the liver via LDL receptor in the liver, thereby indirectly transferring cholesterol to the liver.
  • HDL takes up apoprotein E secreted from macrophage and the like to become apoprotein E-containing HDL rich in CE, and then is directly taken up by the liver via LDL receptor or remnant receptor.
  • HDL particles are not taken up by the liver and only CE in HDL is selectively taken up by hepatocytes.
  • HDL particles are taken up by hepatocytes via what is called an HDL receptor in the liver.
  • WO95/06626 discloses Wiedendiol-A and Wiedendiol-B as CETP activity inhibitors. However, this publication does not contain any description suggesting the compound of the present invention.
  • JP-B-45-11132, JP-B-45-2892, JP-B-45-2891, JP-B-45-2731 and JP-B-45-2730 disclose mercaptoanilides substituted by higher fatty acid such as o-isostearoylaminothiophenol and the like, as a compound having an action to prevent arteriosclerosis.
  • these publications only mention the presence of an effect to prevent arteriosclerosis and lack description of Experimental Example that support the effect, much less a description of inhibition of CETP activity.
  • no description is found that suggests the compound of the present invention.
  • JP-T-2001-512416 discloses a biaryl compound that inhibits CETP.
  • this publication has no description that suggests the compound of the present invention.
  • WO00/17164, WO00/17166 and WO01/40190 disclose 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline as a CETP inhibitor.
  • these publications contain no description that suggests the compound of the present invention.
  • JP-A-2001-106666 and WO01/10825 disclose carbamate derivatives characterized in that phenyl group has an oxime ether group.
  • the compounds of these publications are compounds useful as antimicrobial agents for agriculture or gardening, and they lack a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • WO00/69810 discloses compounds such as 3-(4- ⁇ [N-[3-(2,6-dichlorophenyl)acryloyl]-N-(4-tert-butylbenzyl)amino]methyl ⁇ benzoylamino)propionic acid and the like.
  • the compound of this publication is useful as a glucagon antagonist, and this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • WO99/67204 discloses compounds such as 1-[N-(4-chlorobenzyl)-N-(N,N-dimethylcarbamoyl)aminomethyl]-4-guanidinomethylbenzene and the like.
  • the compound of this publication is useful as an analgesic, and this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • WO99/44987 and U.S. Pat. No. 6,218,426 disclose compounds such as N-(4-tert-butylbenzyl)-N-[4-(guanidinomethyl)benzyl]benzamide and the like useful as a gonadotropin-releasing hormone antagonist/agonist.
  • this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • WO97/24328 discloses 2-amino-heterocyclic compounds such as N,N-bis(2,4-dimethoxybenzyl)-N′-(4-methoxyphenyl)urea and the like.
  • the compound of this publication is useful as a leukotriene synthesis inhibitor and this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • WO96/10559 discloses urea derivatives such as 1-benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6-trimethylphenyl)urea and the like.
  • the compound of this publication is useful as an acyl-CoA:cholesterol acyltransferase inhibitor and this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • U.S. Pat. No. 4,623,662 discloses that urea compounds such as 1-benzyl-1-(2,4-dichlorobenzyl)-3-(2,4-dimethylphenyl)urea and the like are useful as acyl-CoA:cholesterol acyltransferase inhibitors.
  • this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • U.S. Pat. No. 4,473,579 discloses urea compounds such as 1,1-dibenzyl-3-(2,4-dimethylphenyl)-3-phenylurea and the like.
  • the compound of this publication is useful as an acyl-CoA:cholesterol acyltransferase inhibitor and this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • U.S. Pat. Nos. 4,122,255, 4,064,125, 4,151,354 and 4,127,606 disclose compounds such as N-[[2-[3-(dimethylamino)propoxy]phenyl]methyl]-3-phenyl-N-(phenylmethyl)-2-propenamide and the like.
  • the compounds of these publications are useful as antiinflammatory agents and they lack a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • WO99/18066 discloses amide carboxylic acid compounds such as ethyl 2-butyl-3-[4-[2-[N-benzyl-(4-pyridin-2-yl)amino]ethoxy]phenyl]propionate and the like having useful lipid-lowering action and the like.
  • this publication lacks a disclosure of usefulness as a CETP activity inhibitor, or even a description suggestive thereof.
  • this publication lacks a disclosure of a structure such as the compound of the present invention, or even a description suggestive thereof.
  • WO00/18724 discloses a compound having a structure similar to that of the present invention and a CETP inhibitory activity. To be specific, the following formula is disclosed.
  • R 2 and R 3 form a hetero ring or cycloalkenyl in combination
  • the compound is structurally similar to the present invention.
  • this invention lacks a concrete disclosure (Example) of ring B as shown in the present invention.
  • this invention is distinct from the present invention in that the invention always has R 1 (haloalkyl, haloalkenyl, haloalkoxyalkyl or haloalkenyloxyalkyl).
  • this invention does not disclose a concrete structure as the compound of the present invention, not to mention a description suggestive thereof.
  • the present invention aims at providing a novel compound that selectively inhibits the activity of CETP.
  • the present invention also aims at providing a compound useful as a prophylactic or therapeutic agent of arteriosclerosis or hyperlipidemia, which increases HDL cholesterol and simultaneously decreases LDL cholesterol and triglyceride by selectively inhibiting the activity of CETP, and which is free of a CYP inhibitory effect.
  • the present inventors have conducted intensive studies in an attempt to achieve the above-mentioned objects and found that the compounds shown in the following [1] to [13] have an effect to selectively inhibit the activity of CETP (hereinafter to be referred to as a CETP inhibitory effect), and are useful pharmaceutical agents, particularly, prophylactic or therapeutic agents of arteriosclerosis or hyperlipidemia. Moreover, they have found that a structure such as the formula (1) provides a potent CETP inhibitory effect, which resulted in the completion of the present invention. More particularly, the following [1] to [76] are provided.
  • R 60 , R 61 and R 62 are the same or different and each is a hydrogen atom, a halogen atom, a nitro group, an amino group, a hydroxyl group, a cyano group, an acyl group, a C 1-6 alkoxy group, a C 2-6 alkenyl group or a C 1-6 alkyl group (wherein C 1-6 alkyl group is optionally substituted by hydroxyl group or —COOR 14 (wherein R 14 is as defined above)) or a prodrug thereof or a pharmaceutically acceptable salt thereof.
  • R 14 is as defined above
  • R 60 and R 61 are as defined above or a prodrug thereof or a pharmaceutically acceptable salt thereof.
  • A is —N(R 7 ) (R 8 ) (wherein R 7 and R 8 are as defined in the above-mentioned [1]) or a prodrug thereof or a pharmaceutically acceptable salt thereof.
  • R 7 is a C 1-6 alkyl group or a prodrug thereof or a pharmaceutically acceptable salt thereof.
  • halogen atom is a chlorine atom, a bromine atom, a fluorine atom and the like.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 60 , R 61 or R 62 it is preferably a chlorine atom or a fluorine atom, and a preferable halogen atom as a substituent for the C 4-10 cycloalkylalkyl group for R 7 , R 8 , R 11 , R 12 or R 13 is chlorine atom or fluorine atom.
  • the “C 2-6 alkenyl group” is a straight chain or optionally branched alkenyl group having 2 to 6 carbon atoms, such as ethenyl group (vinyl group), 1-propenyl group, 2-propenyl group (allyl group), isopropenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-methyl-1-propenyl group, 1-methyl-2-propenyl group, 2-methyl-2-propenyl group, 1-ethylvinyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1,2-dimethyl-1-propenyl group, 1,2-dimethyl-2-propenyl group, 1-ethyl-1-propenyl group, 1-ethyl-2-propenyl group, 1-methyl-1-butenyl group, 2-methyl-1-butenyl group, 1-isopropylvin
  • the “C 1-6 alkyl group” is a straight chain or optionally branched alkyl group having 1 to 6 carbon atoms, such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, hexyl group and the like, preferably a straight chain or optionally branched alkyl group having 1 to 4 carbon atoms. Particularly preferred are methyl group, ethyl group and isopropyl group.
  • R 20 and R 21 are each preferably a methyl group.
  • R 6 , R 60 , R 61 or R 62 it is preferably a methyl group or an ethyl group
  • R 7 , R 8 , R 11 , R 12 or R 13 it is preferably an ethyl group, a propyl group or a butyl group
  • R 9 or R 10 it is preferably a methyl group or an ethyl group.
  • a referable C 1-6 alkyl group as a substituent for the C 4-10 cycloalkylalkyl group for R 7 , R 8 , R 11 , R 12 or R 13 is a methyl group or an ethyl group.
  • R 14 it is preferably a methyl group or an ethyl group.
  • C 1-6 alkyl group optionally substituted by halogen atoms is the aforementioned C 1-6 alkyl group optionally substituted by the aforementioned halogen atoms, such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, hexyl group, trifluoromethyl group, 1- or 2-chloroethyl group, 1- or 2-bromoethyl group, 1- or 2-fluoroethyl group, 1-, 2- or 3-chloropropyl group, 1-, 2- or 3-bromopropyl group, 1-, 2- or 3-fluoropropyl group, 1-, 2-, 3- or 4-chlorobutyl group, 1-, 2-, 3- or 4-bromobutyl group, 1-, 2-,
  • the “C 1-6 alkoxy group” means a straight chain or branched chain alkoxy group having 1 to 6 carbon atoms, such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, tert-butoxy group, pentyloxy group, tert-pentyloxy group and hexyloxy group.
  • Particularly preferred are methoxy group and ethoxy group.
  • R 6 , R 60 , R 61 or R 62 it is preferably a methoxy group, and a preferable C 1-6 alkoxy group as a substituent for the C 4-10 cycloalkylalkyl group for R 7 , R 8 , R 11 , R 12 or R 13 is a methoxy group or an ethoxy group.
  • the “C 1-6 alkoxy group optionally substituted by halogen atoms” is the aforementioned C 1-6 alkoxy group optionally substituted by the aforementioned halogen atoms, such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, tert-butoxy group, pentyloxy group, tert-pentyloxy group, hexyloxy group, trifluoromethoxy group, 1- or 2-chloroethoxy group, 1- or 2-bromoethoxy group, 1- or 2-fluoroethoxy group, 1-, 2- or 3-chloropropoxy group, 1-, 2- or 3-bromopropoxy group, 1-, 2- or 3-fluoropropoxy group, 1-, 2-, 3- or 4-chlorobutoxy group, 1-, 2-, 3- or 4-bromobutoxy group, 1-, 2-, 3- or 4-fluorobutoxy group and the like.
  • Preferred are methoxy group, ethoxy group and trifluoromethoxy
  • C 1-6 alkylthio group optionally substituted by halogen atoms is one wherein the C 1-6 alkylthio group is optionally substituted by the aforementioned halogen atoms, which is exemplified by methylthio group, ethylthio group, propylthio group, isopropylthio group, butylthio group, tert-butylthio group, pentylthio group, tert-pentylthio group, hexylthio group, trifluoromethylthio group, 1- or 2-chloroethylthio group, 1- or 2-bromoethylthio group, 1- or 2-fluoroethylthio group, 1-, 2- or 3-chloropropylthio group, 1-, 2- or 3-bromopropylthio group, 1-, 2- or 3-fluoropropylthio group, 1-, 2-, 3- or 4-chlorobutylthio group, 1-,
  • the “C 4-10 cycloalkylalkyl group” is a C 1-3 alkyl group substituted by C 3-7 cycloalkyl group.
  • the “C 3-7 cycloalkyl group” means a cycloalkyl group having 3 to 7 carbon atoms, which is exemplified by cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and cycloheptyl group.
  • Preferred is cycloalkyl group having 3 to 6 carbon atoms, which is specifically cyclopropyl group, cyclobutyl group, cyclopentyl group or cyclohexyl group.
  • C 1-3 alkyl group means a straight chain or optionally branched alkyl group having 1 to 3 carbon atoms, which is exemplified by methyl group, ethyl group, propyl group and isopropyl group. Preferred are methyl group, ethyl group and propyl group.
  • C 4-10 cycloalkylalkyl group examples include cyclopropylmethyl group, cyclobutylmethyl group, cyclopentylmethyl group, cyclohexylmethyl group, cycloheptylmethyl group, cyclopentylethyl group (1- or 2-(cyclopentyl)ethyl group), cyclohexylethyl group (1- or 2-(cyclohexyl)ethyl group), cyclopentylpropyl group (1-, 2- or 3-(cyclopentyl)propyl group) and cyclohexylpropyl group (1-, 2- or 3-(cyclohexyl)propyl group).
  • cycloalkylalkyl group preferably having 3 to 7 carbon atoms, which is specifically cyclopropylmethyl group, cyclobutylmethyl group, cyclopentylmethyl group or cyclohexylmethyl group.
  • a preferable C 4-10 cycloalkylalkyl group for R 7 , R 8 , R 11 , R 12 or R 13 is cyclopentylmethyl group, cyclohexylmethyl group or 2-(cyclopentyl)ethyl group.
  • acyl group includes alkylcarbonyl groups such as acetyl group, propionyl group, butyryl group, pivaloyl group and the like; and arylcarbonyl groups such as benzoyl group, naphthoyl and the like. Preferred is acetyl group.
  • R 6 , R 60 , R 61 or R 62 it is preferably an acetyl group, a preferable acyl group as a substituent for the C 4-10 cycloalkylalkyl group for R 7 , R 8 , R 11 , R 12 , or R 13 is acetyl group.
  • the “aryl group” is a phenyl group, a naphthyl group, a biphenyl group and the like, with preference given to a phenyl group.
  • heterocyclic residue a 5- to 8-membered aromatic heterocyclic group containing, besides carbon atom, 1 to 4 heteroatoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, a bicyclic or tricyclic heterocyclic group condensed therewith and the like can be entioned.
  • Examples thereof include pyrrolyl group (1-, 2- or 3-pyrrolyl group), furyl group (2- or 3-furyl group), thienyl group (2- or 3-thienyl group), imidazolyl group (1-, 2-, 4- or 5-imidazolyl group), oxazolyl group (2-, 4- or 5-oxazolyl group), thiazolyl group (2-, 4- or 5-thiazolyl group), pyrazolyl group (1-, 3-, 4- or 5-pyrazolyl group), isoxazolyl group (3-, 4- or 5-isoxazolyl group), isothiazolyl group (3-, 4- or 5-isothiazolyl group), oxadiazolyl group (1,2,4-oxadiazol-3 or 5-yl group, 1,3,4-oxadiazol-2-yl group, 1,2,5-oxadiazol-3-yl group), thiadiazolyl group (1,2,4-thiadiazol-3 or 5-yl group, 1,3,4-thiadiazol-2-y
  • an optionally condensed 3- to 7-membered carbon ring such as C 6-10 arene (C 6-10 aryl) (e.g., benzene (phenyl), naphthalene (naphthyl) and the like), C 3-7 cycloalkane (cycloalkyl) (e.g., cyclopropane (cyclopropyl), cyclobutane (cyclobutyl), cyclopentane (cyclopentyl), cyclohexane (cyclohexyl), cycloheptane (cycloheptyl) etc.), C 3-7 cycloalkene (C 3-7 cycloalkenyl group) (e.g., cyclopropene (cyclopronyl), cyclobutene (cyclobutenyl), cyclopentene (cyclopentenyl), cyclohexene (cyclohexeny
  • the above-mentioned homocyclic ring may have, for example, (1) a C 1-6 alkyl group optionally substituted by halogens (particularly, C 1-6 alkyl group substituted by halogens is preferable), (2) a C 3-10 cycloalkyl group, (3) a C 2-10 alkenyl group, (4) a C 2-10 alkynyl group, (5) a C 6-10 aryl group, (6) a C 7-20 aralkyl group, (7) a nitro group, (8) a hydroxy group, (9) a mercapto group, (10) a oxo group, (11) a thioxo group, (12) a cyano group, (13) a carbamoyl group, (14) a carboxyl group, (15) a C 1-6 alkoxycarbonyl group (e.g., methoxycarbonyl group, ethoxycarbonyl group etc.), (16) a sulfo, (17
  • Preferable examples of the “homocyclic ring optionally having a substituent” formed by R 3 and R 4 or R 4 and R 5 together with carbon atoms bonded thereto are C 3-7 cycloalkane and benzene, and more preferable examples are cyclopentane and cyclohexane.
  • heterocyclic ring a 5- to 8-membered heterocyclic group containing, besides carbon atom, 1 to 4 heteroatoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, and a bicyclic or tricyclic heterocyclic group condensed therewith and the like can be mentioned.
  • heterocyclic ring examples include (1) a 5-membered heterocyclic ring containing, besides carbon atom, 1 to 4 heteroatoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, such as thiophene (thienyl group), furan (furyl group), pyrrole (pyrrolyl group), pyrroline (pyrrolinyl group), pyrrolidine (pyrrolidinyl group), 1,3-dioxole (1,3-dioxolyl group), oxazole (oxazolyl group), thiazole (thiazolyl group), pyrazole (pyrazolyl group), imidazole (imidazolyl group), imidazoline (imidazolinyl group), isoxazole (isoxazolyl group), isothiazole (isothiazolyl group), furazan (furazanyl group), 1,2,3-thiadiazole (1,2,3-thiadiazolyl group), 1,
  • bicyclic or tricyclic condensed heterocyclic ring a bicyclic or tricyclic condensed heterocyclic ring containing, besides carbon atom, 1 to 4 heteroatoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, such as benzofuran (benzofuryl group), benzothiazole (benzothiazolyl group), benzoxazole (benzoxazolyl group), tetrazolo[1,5-b]pyridazine (tetrazolo[1,5-b]pyridazinyl group), triazolo[4,5-b]pyridazine (triazolo[4,5-b]pyridazinyl group), benzimidazole (benzimidazolyl group), quinoline (quinolyl group), isoquinoline (isoquinolyl group), cinnoline (cinnolinyl group), phthalazine (phthalazinyl group), quinazoline (quinazolin
  • the above-mentioned heterocyclic ring may have, for example, (1) a C 1-6 alkyl group, (2) a C 2-6 alkenyl group, (3) a C 2-6 alkynyl group, (4) a C 3-6 cycloalkyl group, (5) a cycloalkenyl group, (6) a C 7-11 aralkyl group, (7) a C 6-14 aryl group, (8) a C 1-6 alkoxy group, (9) a C 6-14 aryloxy group (e.g., phenoxy group etc.), (10) a C 1-6 alkanoyl group (e.g., formyl group, acetyl group, propionyl group, n-butyryl group, iso-butyryl group etc.), (11) a C 6-14 arylcarbonyl group (e.g., benzoyl group etc.), (12) a C 1-6 alkanoyloxy group (e.g., formy
  • heterocyclic ring optionally having a substituent” formed by R 3 and R 4 or R 4 and R 5 together with carbon atoms bonded thereto are thiophene, furan, pyrrole, pyrroline, oxazole, thiazole, pyrazole, imidazole, imidazoline, isoxazole, isothiazole, furazan, 1,2,3-thiadiazole, 1,2,5-thiadiazole, 1,2,3-triazole, 1,2,3-triazine, 1,2,4-triazine, 1,2,3-triazolidine, 2,2-difluoro-1,3-dioxole and 2,2,3,3-tetrafluoro-1,4-dioxane.
  • the substituent of the “homocyclic ring optionally having substituents” and the substituent of the “heterocyclic ring optionally having substituents” are preferably selected from the group consisting of (1) C 1-6 alkyl group optionally substituted by halogen atoms, (2) nitro group, (3) hydroxy group, (4) mercapto group, (5) cyano group, (6) carbamoyl group, (7) carboxyl group, (8) C 1-6 alkoxycarbonyl group, (9) sulfo group, (10) halogen atom, (11) C 1-6 alkoxy group, (12) C 1-6 alkylthio group, (13) C 1-6 alkylsulfinyl group, (14) C 1-6 alkylsulfonyl group, (15) amino group, (16) mono- or di-C 1-4 alkylamino group, (17) C 1-6 alkanoyl group and (18) C 1-6 alkanoyloxy group.
  • the “pharmaceutically acceptable salt” may be any as long as it forms a nontoxic salt with the aforementioned compound represented by the formula (1).
  • examples thereof include, but are not limited to, salts with various inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, carbonate, hydrogen carbonate, perchlorate and the like; salts with organic acids such as formate, acetate, trifluoroacetate, propionate, oxalate, glycolate, succinate, lactate, maleate, hydroxymaleate, methylmaleate, fumarate, adipate, tartrate, malate, citrate, benzoate, cinnamate, ascorbate, salicylate, 2-acetoxybenzoate, nicotinate, isonicotinate and the like; sulfonates such as methanesulfonate, ethanesulfonate, isethionate, benzenesul
  • the above-mentioned compound represented by the formula (1) may have various isomers.
  • E form and Z form are present as geometric isomers, and when an asymmetric carbon atom exists, enantiomer and diastereomer as stereoisomers based thereon exist, and a tautomer can exist. Accordingly, the present invention encompasses all of these isomers and mixtures thereof.
  • the compound of the present invention encompasses prodrug compounds and metabolites.
  • prodrug compound a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group and which, after administration to the body, restores to the original compound to show its inherent efficacy, including a complex and a salt free of covalent bond.
  • a compound wherein the carboxyl group of the compound represented by the formula (1) is modified by ethyl group, pivaloyloxymethyl group, 1-(acetyloxy)ethyl group, 1-(ethoxycarbonyloxy)ethyl group, 1-(cyclohexyloxycarbonyloxy)ethyl group, carboxylmethyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group, phenyl group, o-tolyl group and the like; a compound wherein the hydroxyl group of the compound represented by the formula (1) is modified by acetyl group, propionyl group, isobutyryl group, pivaloyl group, benzoyl group, 4-methylbenzoyl group, dimethylcarbamoyl group or sulfo group; a compound wherein the amino group of the compound represented by the formula (1) is modified by he
  • R 1 is preferably a C 1-6 alkyl group optionally substituted by halogen atoms, more preferably a trifluoromethyl group.
  • R 2 is preferably a halogen atom, a C 1-6 alkyl group optionally substituted by halogen atoms or a cyano group, more preferably a trifluoromethyl group or a cyano group.
  • R 3 and R 4 are each preferably a hydrogen atoms, a halogen atom, a C 1-6 alkyl group optionally substituted by halogen atoms, a C 1-6 alkoxy group optionally substituted by halogen atoms, a C 1-6 alkylthio group optionally substituted by halogen atoms or R 3 and R 4 form a homocyclic ring together with carbon atoms bonded thereto.
  • R 5 is preferably a hydrogen atom.
  • R 6 is preferably a hydrogen atom or a C 1-6 alkyl group, more preferably a hydrogen atom, a methyl group or an ethyl group.
  • n is preferably 0, 1 or 2.
  • Ring B and (R 6 ) n are each preferably
  • R 60 , R 61 and R 62 are as defined above, more preferably
  • R 60 and R 61 are as defined above.
  • A is preferably —N(R 7 ) (R 8 ), more preferably that wherein R 7 is a C 1-6 alkyl group and R 8 is a C 4-10 (cycloalkylalkyl group optionally substituted by —(CH 2 ) r —COOR 10 (wherein r and R 10 are as defined above) or a C 1-6 alkyl group substituted by carboxyl group.
  • the compound of the present invention, a prodrug thereof and a pharmaceutically acceptable salt thereof have superior CETP inhibitory activity in mammals (e.g., human, monkey, bovine, horse, dog, cat, rabbit, rat, mouse and the like), and can be used as CETP activity inhibitors.
  • mammals e.g., human, monkey, bovine, horse, dog, cat, rabbit, rat, mouse and the like.
  • a prodrug thereof and a pharmaceutically acceptable salt thereof are useful as pharmaceutical agents effective for the prophylaxis or treatment of the diseases in which CETP is involved (e.g., hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, angina, ischemia, heart ischemia, thrombosis, cardiac infarction, reperfusion injury, angioplasty restenosis, hypertension, diabetic vascular complications, obesity or endotoxemia etc.), particularly as prophylactic or therapeutic agents for hyperlipidemia or arteriosclerotic diseases.
  • diseases in which CETP e.g., hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial
  • a prodrug thereof or a pharmaceutically acceptable salt thereof is used as a pharmaceutical preparation, it is generally admixed with a pharmacologically acceptable carrier, excipient, diluent, filler, disintegrant, stabilizer, preservative, buffer, emulsifier, aromatic, coloring agent, sweetening agent, thickening agent, corrigent, dissolution aids, and other additives, which are known per se, specifically water, vegetable oil, alcohol such as ethanol and benzyl alcohol, polyethylene glycol, glycerol triacetate gelatin, carbohydrates such as lactose, starch and the like, magnesium stearate, talc, lanolin, petrolatum and the like, and can be administered orally or parenterally in the form of tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche, aerosol, elixir, suspension, emulsion, syrup and the like.
  • a pharmacologically acceptable carrier excipient
  • the dose of the pharmaceutical agent of the present invention varies depending on the kind and severity of the disease, the compound to be administered and administration route, age, sex and body weight of patients and the like, it is generally about 1-1000 mg, particularly about 50 mg-800 mg in the amount of the compound represented by the formula (1) of the present invention, a prodrug thereof or a pharmaceutically acceptable salt thereof per day for an adult by oral administration.
  • the pharmaceutical agent of the present invention may be administered alone or concurrently with a different prophylactic or therapeutic agent for hyperlipidemia and/or a prophylactic or therapeutic agent for arteriosclerotic diseases, or may be used concurrently with a different pharmaceutical agent (e.g., therapeutic agent for obesity, therapeutic agent for diabetes, therapeutic agent for hypertension, therapeutic agent for arteriosclerosis, therapeutic agent for coronary artery disease etc.).
  • a different pharmaceutical agent e.g., therapeutic agent for obesity, therapeutic agent for diabetes, therapeutic agent for hypertension, therapeutic agent for arteriosclerosis, therapeutic agent for coronary artery disease etc.
  • a different therapeutic agent for hyperlipidemia is expected to provide an extremely superior synergistic effect of particularly remarkable suppression of blood cholesterol.
  • current use means a combined use of the compound of the present invention, a prodrug thereof or a pharmaceutically acceptable salt thereof with a different pharmaceutical agent, such as a therapeutic agent for hyperlipidemia, wherein the mode of use thereof is not particularly limited.
  • a pharmaceutical composition containing the compound of the present invention, a prodrug thereof or a pharmaceutically acceptable salt thereof and a different pharmaceutical agent includes both the administration of a pharmaceutical composition containing the compound of the present invention, a prodrug thereof or a pharmaceutically acceptable salt thereof and a different pharmaceutical agent, and the simultaneous or staggered administration of respective preparations produced separately without mixing.
  • the dose of the different pharmaceutical agent to be used concurrently varies depending on the kind and severity of the disease, administration route, age, sex and body weight of patients and the like, it is generally about 1-1000 mg, particularly about 50 mg-800 mg thereof per day for an adult by oral administration.
  • statin pharmaceutical agents such as lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin and the like can be mentioned.
  • mazindol As a therapeutic agent for obesity to be used concurrently with the pharmaceutical agent of the present invention, mazindol and the like can be mentioned.
  • insulin preparations e.g., glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide etc.
  • insulin secretagogues e.g., nateglinide etc.
  • sulfonamides e.g., glybuzole etc.
  • biguanides e.g., metformin hydrochloride, buformin hydrochloride etc.
  • ⁇ glucosidase inhibitors e.g., voglibose, acarbose etc.
  • insulin sensitizers e.g., pioglitazone hydrochloride etc.
  • loop diuretics e.g., furosemide sustained-release preparation etc.
  • angiotensin converting enzyme inhibitors e.g., captopril, captopril sustained-release preparation, enalapril maleate, alacepril, delapril hydrochloride, cilazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, temocapril hydrochloride, quinapril hydrochloride, trandrapril, perindopril erbumine etc.), angiotensin II receptor antagonists (e.g., losartan potassium, candesartan cilexetil etc.), Ca antagonists (e.g., nicardipine hydrochloride, nicardipine hydrochloride sustained-release preparation, nilvadipine, nifedipine,
  • the pharmaceutical agent of the present invention can be administered not only to humans but also to other mammals (e.g., monkey, bovine, horse, dog, cat, rabbit, rat, mouse and the like).
  • mammals e.g., monkey, bovine, horse, dog, cat, rabbit, rat, mouse and the like.
  • reaction in each step may be carried out according to a conventional method, wherein isolation and purification are performed by appropriately selecting or combining conventional methods, such as crystallization, recrystallization, column chromatography, preparative HPLC and the like.
  • the production method of the compound represented by the formula (1) is exemplarily shown in the following.
  • This step is directed to a general reductive amination.
  • the compound represented by the formula (2) is reacted with a compound represented by the formula (3) in the presence of a reducing agent in a solvent to give a compound represented by the formula (4).
  • ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as acetic acid, N,N-dimethylformamide and the like; and the like can be mentioned, which can be used alone or in combination.
  • Preferable solvents in this reaction are chloroform and dichloromethane.
  • sodium triacetoxyborohydride sodium cyanoborohydride, sodium borohydride and the like can be mentioned.
  • a preferable reducing agent in this reaction is sodium triacetoxyborohydride.
  • This step is directed to a general alkylation.
  • a compound represented by the formula (4) is reacted with a compound represented by the formula (5) in a solvent in the presence of a base to give one of the object compounds, which is represented by the formula (1-a).
  • ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is N,N-dimethylformamide.
  • alkali metal hydrides e.g., sodium hydride, potassium hydride etc.
  • alkali metal alkoxides e.g., sodium ethoxide, sodium methoxide, potassium tert-butoxide etc.
  • alkyllithiums e.g., n-butyllithium, sec-butyllithium etc.
  • alkali metal amides e.g., lithium diisopropylamide, sodium amide, lithium bistrimethylsilylamide etc.
  • alkali metal carbonates e.g., sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate etc.
  • alkali metal hydroxides e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide etc.
  • alkali metal phosphates e.g., sodium phosphate, potassium phosphate etc.
  • organic bases e.g., triethylamine, pyridine, N-methylmorpholine etc.
  • the obtained object compound may be subjected to a salt-forming reaction to give a desired salt.
  • This step is directed to a general reductive amination.
  • a compound represented by the formula (6) is reacted with a compound represented by the formula (3) in a solvent in the presence of a reducing agent to give a compound represented by the formula (7).
  • ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as N,N-dimethylformamide and the like; and the like can be mentioned, which can be used alone or in combination.
  • Preferable solvents in this reaction are dichloromethane and toluene.
  • sodium triacetoxyborohydride sodium cyanoborohydride, sodium borohydride, lithium hydride, aluminum hydride and the like can be mentioned.
  • a preferable reducing agent in this reaction is sodium borohydride.
  • the formula (6) is reacted with the formula (3) to once give a Schiff base, which is followed by a reduction.
  • azeotropic dehydration may be conducted in a solvent such as benzene, toluene, ethanol and the like without catalyst or in the presence of an acid catalyst such as hydrochloric acid, acetic acid and the like, or a method using a dehydrating agent such as molecular sieves and the like in an aprotic solvent such as methylene chloride, toluene and the like may be employed.
  • a compound represented by the formula (8) which is obtained by treating the formula (2) by a general reduction, is reacted with thionyl chloride in a solvent such as toluene, tetrahydrofuran, chloroform and the like to give a compound wherein hydroxyl group of the formula (8) is chlorinated.
  • a similar reaction as in Step 1-2 using the obtained compound and a compound represented by the formula (7) gives one of the object compounds, which is represented by the formula (1-a)
  • This step is directed to a general reductive amination.
  • a compound represented by the formula (2) is reacted with a compound represented by the formula (9) in a solvent in the presence of a reducing agent to give a compound represented by the formula (10).
  • ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as N,N-dimethylformamide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is dichloromethane.
  • sodium triacetoxyborohydride sodium cyanoborohydride, sodium borohydride and the like can be mentioned.
  • a preferable reducing agent in this reaction is sodium triacetoxyborohydride.
  • Step 1-2 This step is directed to a general nucleophilic substitution reaction.
  • a compound represented by the formula (10) is reacted with a compound represented by the formula (11) to give one of the object compounds, which is represented by the formula (1-a).
  • a compound represented by the formula (10) is reacted with compound (12) in a solvent.
  • the obtained residue is reacted with hydrazine hydrate in a solvent in the presence of an acid to give a compound represented by the formula (1-b), which is one of the object compounds.
  • ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like
  • hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like
  • halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like
  • ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like
  • polar solvents such as N,N-dimethylformamide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is dichloromethane.
  • ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is 1,2-dimethoxyethane.
  • inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid and the like
  • organic acids such as trifluoroacetic acid, trichloroacetic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid and the like
  • a mixture thereof can be mentioned, with preference given to methanesulfonic acid.
  • a compound represented by the formula (10) is reacted with cyanogen bromide in a solvent in the presence of a base, and the obtained residue is reacted with hydroxylamine in a solvent.
  • the obtained residue is reacted with an acylating agent, such as acid chloride represented by the formula (13) and the like, in a solvent to give a compound represented by the formula (1-c), which is one of the object compounds.
  • solvent to be used for the first reaction for example, alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like; ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as N,N-dimethylformamide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is methanol.
  • alkali metal carbonates e.g., sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate etc.
  • alkali metal phosphates e.g., sodium phosphate, potassium phosphate etc.
  • organic bases e.g., triethylamine, pyridine, N-methylmorpholine etc.
  • ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like
  • hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like
  • halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like
  • alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like
  • polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is dioxane.
  • ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents such as benzene, toluene, hexane, xylene and the like; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ester solvents such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide and the like; and the like can be mentioned, which can be used alone or in combination.
  • a preferable solvent in this reaction is pyridine.
  • A, B and R 1 to R 6 may be further subjected to conversion of a functional group according to a known method, after synthesis of compound (1) in the above-mentioned production method.
  • a functional group conversion reaction for example, when the terminal of substituent A is an ester, the obtained compound (1-a) is subjected to a conventional ester hydrolysis, whereby a compound having a carboxyl group as the terminal of substituent A can be easily obtained.
  • the solvent to be used for this ester hydrolysis reaction for example, ether solvents such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; alcohol solvents such as methanol, ethanol, isopropyl alcohol, tert-butanol and the like, and water can be mentioned, which may be used alone or in combination.
  • metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like, and the like can be mentioned.
  • a compound represented by the formula (2) which is a starting material of the above-mentioned production method, can be produced according to a conventionally known method. In the following, some examples thereof are explained.
  • R 3 , R 4 , R 5 and R 7 are as defined above, and —CH 2 R 8a is a group corresponding to the aforementioned R 8 .
  • Aniline represented by the formula (15) is reacted with an acid halide and the like in the presence or absence of a base under cooling to heating in an organic solvent, water, or without solvent, whereby a compound represented by the formula (16) can be synthesized (Step 4-1).
  • the compound represented by the formula (16) is reacted with a reducing agent such as lithium aluminum hydride, Red-Al, sodium borohydride and the like under cooling to heating in an organic solvent, whereby a compound represented by the formula (17) can be synthesized (Step 4-2).
  • the compound represented by the formula (17) is reacted with alkyl halide and the like in the presence or absence of a base under cooling to heating in an organic solvent or water, or without solvent, whereby a compound represented by the formula (18) can be synthesized (Step 4-3).
  • the compound represented by the formula (18) is reacted using a Vilsmeier reagent prepared from phosphorus oxychloride and N,N-dimethylformamide and the like under cooling to heating in an organic solvent or without solvent, whereby a compound represented by the formula (2-a), which is one of the desired starting materials, can be synthesized (Step 4-4).
  • R 3 , R 4 , R 5 , R 11 , R 12 and R 13 are as defined above.
  • Phenol represented by the formula (19) is reacted with alcohol represented by the formula; (R 11 )(R 12 ) (R 13 )COH (wherein R 11 , R 12 and R 13 are as defined above) in the presence of triphenylphosphine using a condensing agent such as diethyl azodicarboxylate and the like under cooling to heating in an organic solvent or water, or without solvent, whereby a compound represented by the formula (20) can be synthesized (Step 5-1).
  • a condensing agent such as diethyl azodicarboxylate and the like
  • the compound represented by the formula (20) is reacted using a Vilsmeier reagent prepared from phosphorus oxychloride and N,N-dimethylformamide and the like under cooling to heating in an organic solvent or without solvent, whereby a compound represented by the formula (2-b), which is one of the desired starting materials, can be synthesized (Step 5-2).
  • R 3 , R 4 , R 5 , R 11 and R 12 are as defined above, and X is a halogen atom.
  • Halobenzene represented by the formula (21) and butyllithium are reacted in an organic solvent under cooling to room temperature and a lithio form generated is treated with ketone, aldehyde and the like, whereby a compound represented by the formula (22) can be synthesized (Step 6-1).
  • the compound represented by the formula (22) is hydrogenated in the presence of a catalyst such as palladium hydroxide and the like at room temperature or under heating in an organic solvent or water, whereby a compound represented by the formula (23) can be synthesized (Step 6-2).
  • the compound represented by the formula (23) is reacted using a brominating agent such as bromosuccinimide and the like under cooling to heating in an organic solvent or without solvent, whereby a compound represented by the formula (24) can be synthesized (Step 6-3).
  • a brominating agent such as bromosuccinimide and the like under cooling to heating in an organic solvent or without solvent
  • a compound represented by the formula (24) can be synthesized (Step 6-3).
  • the compound represented by the formula (24) and butyllithium are reacted in an organic solvent under cooling to room temperature and a lithio form generated is treated with N,N-dimethylformamide and the like, whereby a compound represented by the formula (2-c), which is one of the desired starting materials, can be synthesized (Step 6-4).
  • R 3 , R 4 , R 5 , R 7 and R 8 are as defined above.
  • a fluorobenzene compound represented by the formula (25) and LDA, butyllithium and the like are reacted in an organic solvent under cooling to room temperature and a lithio form generated is treated with N,N-dimethylformamide and the like, whereby a compound represented by the formula (26) can be synthesized (Step 7-1).
  • the compound represented by the formula (26) is reacted with an amine represented by the formula; (R 7 ) (R 8 )NH in the presence of a base such as potassium carbonate and the like under cooling to heating in an organic solvent or without solvent, whereby a compound represented by the formula (2-d), which is one of the desired starting materials, can be synthesized (Step 7-2).
  • Example 6 In a similar manner as in Example 4, the title compound (50 mg) was obtained from N-[6-(N′-cyclopentylmethyl-N′-ethylamino)indan-5-ylmethyl]-N-[3,5-bis(trifluoromethyl)benzyl]-(pyrimidin-2-yl)amine (68 mg) obtained in Example 6 b) (see Table 2).
  • hexane solution was added dropwise over 1.5 hr to a mixture of tetrahydrofuran (300 ml) and 1.0 M solution (600 ml) of s-butyllithium in hexane, which had been cooled to ⁇ 78° C. and stirred. The stirring was continued for 1 hr and N,N-dimethylformamide (57 ml) was added dropwise. After completion of the dropwise addition, 2N aqueous hydrochloric acid (600 ml) was added and the mixture was allowed to warm to room temperature. This was extracted with hexane and washed with water and saturated brine. The organic layer was dried over sodium sulfate and sodium sulfate was filtered off. The filtrate was concentrated to give the title compound (61.54 g, 52%).
  • the compounds shown in Table 35 can be produced in a similar manner.
  • the mixture was subjected to density gradient centrifugation (227,000 ⁇ g, 4° C., 17 hr) and a fraction showing a specific density of d>1.125 g/mL (HDL 3 fraction) was harvested.
  • the obtained fraction was dialyzed against PBS solution [10 mmol/L Na 2 HPO 4 ; 10 mmol/L NaH 2 PO 4 ; 0.15 mol/L NaCl; 1 mol/L EDTA (pH 7.4)].
  • tritium-labeled cholesterol 37 MBq was dissolved in 95% ethanol, gradually added to the above-mentioned HDL 3 fraction with stirring and incubated at 37° C. for 18 hr.
  • tritium-labeled cholesterol was esterified by the action of lecithin acyl transferase (LCAT) present on the HDL 3 surface and taken up into HDL 3 as tritium-labeled cholesteryl ester ([ 3 H]CE)].
  • LCAT lecithin acyl transferase
  • the donor lipoprotein obtained above was added to plasma of healthy subject to prepare a [ 3 H]CE-HDL 3 -containing plasma (1,000 dpm/ ⁇ L).
  • the compound was dissolved in dimethyl formamide.
  • a solution of the compound or a solvent alone (2 ⁇ L) and the [ 3 H]CE-HDL 3 -containing plasma (100 ⁇ L) were added into a microtube, and this was incubated at 37° C. or 4° C. for 4 hr. After ice-cooling, TBS solution [100 ⁇ L, 20 mmol/L Tris; 0.15 mol/L NaCl (pH 7.4)] containing 1 mol/L magnesium chloride and 2% dextran sulfate was added to each microtube and the mixture was thoroughly stirred.
  • the mixture was centrifuged (10,000 ⁇ g, 4° C., 10 min), and the radioactivity in the obtained supernatant (HDL fraction) was measured with a scintillation counter.
  • the difference in the measurement values obtained by incubation of solvent alone at 4° C. and 37° C. was taken as CETP activity, and the proportion of decrease in the difference in the measurement values of specimen was taken as percent inhibition of CETP activity.
  • the concentration of the compound necessary for inhibiting the CETP activity by 50% was calculated as an IC 50 value. The results are shown in the following.
  • Example No. IC 50 ( ⁇ M) Example No. IC 50 ( ⁇ M) 1 0.23 2 0.08 3 0.24 4 0.18 7 0.27 8 0.63 10 0.23 11 0.63 12 0.25 13 0.58 26 0.47 27 0.58 28 0.44 33 0.56 34 0.22 35 0.35 36 0.34 37 0.80 38 0.47 39 0.88 40 0.39 41 0.51 42 0.70 43 0.55 44 0.36 45 0.49 46 0.39 51 0.41 52 0.37 53 0.70 54 0.79 55 0.77 58 0.715 59 0.43 60 0.78 63 0.64 64 0.75 65 0.29 66 0.87 67 0.26 68 0.28 69 0.34 70 0.54 71 0.44 72 0.39 73 0.19 74 0.40 75 0.41
  • the IC 50 values in Table show average values.
  • Example No. IC 50 ( ⁇ M) Example No. IC 50 ( ⁇ M) 76 0.29 77 0.54 78 0.32 79 0.89 80 0.43 81 0.33 82 0.59 86 0.941 89 0.69 91 0.56 92 0.19 93 0.76 96 0.31 98 0.30 99 0.53 102 0.59 103 0.43 104 0.35 105 0.60 107 0.56 108 0.25 109 0.16 111 0.19 114 0.28 115 0.09 118 0.09 119 0.13 120 0.28 121 0.23 122 0.24 127 0.37 129 0.61 131 0.17 135 0.22 137 0.14 138 0.16 140 0.12 141 0.12 142 0.06 143 0.10
  • the IC 50 values in Table show average values.
  • the compound of the present invention was suspended in 0.5% methyl cellulose solution and orally administered once to a healthy hamster with a plastic gavage needle. Blood was taken at 2 or 4 hr after the administration and CETP activity in plasma was measured according to the following method.
  • the donor lipoprotein obtained above was added to hamster plasma (100 ⁇ L) to prepare [ 3 H]CE-HDL 3 -containing plasma (ca. 1,000 dpm/ ⁇ L).
  • the [ 3 H]CE-HDL 3 -containing plasma was dispensed to two microtubes by 25 ⁇ L each, and one was incubated at 37° C. and the other was incubated at 4° C. for 4 hr each. After ice-cooling, TBS solution (50 ⁇ L) containing 1 mol/L magnesium chloride and 2% dextran sulfate was added to each microtube and the mixture was thoroughly stirred. After keeping at 4° C.
  • CETP activity inhibitory ratio 100 ⁇ [( CETP activity of each compound administration group)/( CETP activity of solvent administration group) ⁇ 100]
  • HDL cholesterol increase content (%) compound Dose (mg/kg) 4 (hr later) 8 (hr later) 115 3 23.3 30.7 118 3 21.1 31.7 142 3 20.3 31.9 143 3 17.0 21.3 154 3 13.3 22.4 157 3 17.9 27.1 158 3 14.8 23.7
  • the HDL cholesterol increase ratios in Table show average values.
  • Foods were prepared (manufactured by Oriental Bio-Service Co.) by adding simvastatin (0.002%), compound (0.2%) of Example 168, or simvastatin (0.002%)+compound (0.2%) of Example 168 to a high cholesterol food, and each food was given to the grouped animals by 100 g/day per rabbit for 15 days.
  • the total blood was taken from the carotid artery under anesthesia, HDL cholesterol content, total cholesterol content and ApoA-I content in plasma were measured.
  • the arteriosclerosis index was calculated from [(total cholesterol content-HDL cholesterol content)/HDL cholesterol content].
  • the HDL 3 fraction was separated from plasma by ultracentrifugation and the cholesterol content of the fraction was measured.
  • arteriosclerotic index, ApoA-I content and HDL 3 cholesterol content are shown based on the value of the control group as 100%.
  • the compound and a salt thereof of the present invention have superior CETP activity inhibitory effect. Therefore, they can decrease IDL, VLDL and LDL that promote arteriosclerosis and increase HDL that acts suppressively. As a result, they are useful as prophylactic or therapeutic agents for hyperlipidemia. In addition, they are useful as prophylactic or therapeutic agents for arteriosclerotic disease and the like.
  • the compound of the present invention can be used concurrently with a different pharmaceutical agent, particularly other therapeutic agents for hyperlipidemia, arteriosclerosis, coronary artery disease, obesity, diabetes or hypertension.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
US10/503,185 2002-08-30 2003-08-29 Dibenzylamine compound and medicinal use thereof Expired - Fee Related US7332514B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/939,359 US7807701B2 (en) 2002-08-30 2007-11-13 Dibenzylamine compounds and pharmaceutical use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002255604 2002-08-30
JP2003107161 2003-04-10
PCT/JP2003/011041 WO2004020393A1 (ja) 2002-08-30 2003-08-29 ジベンジルアミン化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/939,359 Continuation US7807701B2 (en) 2002-08-30 2007-11-13 Dibenzylamine compounds and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
US20050059810A1 US20050059810A1 (en) 2005-03-17
US7332514B2 true US7332514B2 (en) 2008-02-19

Family

ID=31980551

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/503,185 Expired - Fee Related US7332514B2 (en) 2002-08-30 2003-08-29 Dibenzylamine compound and medicinal use thereof
US11/939,359 Expired - Fee Related US7807701B2 (en) 2002-08-30 2007-11-13 Dibenzylamine compounds and pharmaceutical use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/939,359 Expired - Fee Related US7807701B2 (en) 2002-08-30 2007-11-13 Dibenzylamine compounds and pharmaceutical use thereof

Country Status (24)

Country Link
US (2) US7332514B2 (ja)
EP (2) EP1829858A3 (ja)
KR (1) KR100634195B1 (ja)
CN (1) CN1289467C (ja)
AT (1) ATE353870T1 (ja)
AU (1) AU2003261826B2 (ja)
BR (1) BR0306208A (ja)
CA (1) CA2464846C (ja)
CY (1) CY1106425T1 (ja)
CZ (1) CZ2004627A3 (ja)
DE (1) DE60311821T2 (ja)
DK (1) DK1533292T3 (ja)
ES (1) ES2277142T3 (ja)
IL (2) IL161559A0 (ja)
MX (1) MXPA04005350A (ja)
NO (1) NO328886B1 (ja)
NZ (1) NZ532494A (ja)
PT (1) PT1533292E (ja)
RU (1) RU2293078C2 (ja)
SI (1) SI1533292T1 (ja)
SK (1) SK2332004A3 (ja)
TR (1) TR200401413T1 (ja)
WO (1) WO2004020393A1 (ja)
ZA (1) ZA200403137B (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213314A1 (en) * 2006-03-10 2007-09-13 Pfizer Inc Dibenzyl Amine Compounds and Derivatives
US20070213371A1 (en) * 2006-03-10 2007-09-13 Pfizer Inc Dibenzyl Amine Compounds and Derivatives
US20080146620A1 (en) * 2002-08-30 2008-06-19 Japan Tobacco Inc. Dibenzylamine Compounds and Pharmaceutical Use Thereof
US20090023729A1 (en) * 2006-01-31 2009-01-22 Mitsubishi Tanabe Pharma Corporation Trisubstituted amine compound
US20090029994A1 (en) * 2006-01-31 2009-01-29 Mitsubishi Tanabe Pharma Corporation Trisubstituted amine compound
US9000007B2 (en) 2011-09-27 2015-04-07 Dr. Reddy's Laboratories Ltd. 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US9782407B2 (en) 2004-12-31 2017-10-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US12150975B2 (en) 2016-07-27 2024-11-26 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
AU2008201550B2 (en) * 2003-09-26 2011-02-10 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
CN103330703A (zh) * 2003-09-26 2013-10-02 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
EP1670768B1 (en) 2003-10-08 2009-09-09 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP4587685B2 (ja) * 2004-03-23 2010-11-24 セントラル硝子株式会社 ３−ホルミル−５−トリフルオロメチルベンゾニトリル誘導体とその製造方法
ATE402180T1 (de) * 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
AU2005233160B2 (en) 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
MXPA06014716A (es) * 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
BRPI0514133A (pt) 2004-08-05 2008-05-27 Hoffmann La Roche compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AU2006299557A1 (en) * 2005-09-30 2007-04-12 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
US7935727B2 (en) * 2005-10-19 2011-05-03 Merck Sharp & Dohme Corp. CETP inhibitors
CN101384251B (zh) * 2005-12-22 2014-09-03 武田药品工业株式会社 含胰岛素敏化剂的固体制剂
CA2642130C (en) * 2005-12-28 2013-04-02 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
WO2007073934A1 (en) * 2005-12-29 2007-07-05 Novartis Ag Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
US7572823B2 (en) * 2006-02-07 2009-08-11 Hoffmann-La Roche Inc. Heteroaryl carboxamide compounds
NZ569700A (en) * 2006-02-09 2011-09-30 Merck Sharp & Dohme Polymer formulations of CETP inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
KR101172120B1 (ko) 2006-05-10 2012-08-10 노파르티스 아게 Ｃｅｔｐ 억제제로서의 바이시클릭 유도체
GB0609268D0 (en) * 2006-05-10 2006-06-21 Novartis Ag Organic compounds
AU2007250763A1 (en) * 2006-05-11 2007-11-22 Novartis Ag Benzylamine derivatives as CETP inhibitors
EP2049493B1 (en) * 2006-07-31 2012-03-21 Cadila Healthcare Limited Compounds suitable as modulators of hdl
KR100821688B1 (ko) 2006-08-10 2008-04-11 (주)유케이케미팜 암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
MX2009010962A (es) * 2007-04-13 2009-12-16 Kowa Co Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP5319457B2 (ja) * 2008-08-25 2013-10-16 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
US8841478B2 (en) 2008-11-28 2014-09-23 Kowa Company, Ltd. Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
PT2729142T (pt) * 2011-07-08 2018-10-01 Novartis Ag Método de tratamento de aterosclerose em sujeitos com nível elevado de triglicéridos
EP3006430A4 (en) 2013-05-31 2016-11-02 Kowa Co NOVEL FORM OF A PYRIMIDINE COMPOUND WITH DIBENZYLAMINE STRUCTURE

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
US4064125A (en) 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4473579A (en) 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
WO1995006626A1 (en) 1993-09-01 1995-03-09 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
WO1995029672A1 (en) 1994-04-29 1995-11-09 Sanofi Winthrop, Inc. HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS
WO1996010559A1 (en) 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
WO1997024328A1 (en) 1995-12-27 1997-07-10 Bayer Aktiengesellschaft 2-amino-heterocycles and therapeutic uses therefor
WO1998004528A2 (en) 1996-07-31 1998-02-05 Bayer Corporation Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
US5834514A (en) 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
WO1999018066A1 (en) 1997-10-02 1999-04-15 Sankyo Company, Limited Amidocarboxylic acid derivatives
WO1999044987A1 (en) 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
WO1999067204A1 (en) 1998-06-22 1999-12-29 Astrazeneca Ab Novel compounds
WO2000017166A1 (en) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000017164A1 (en) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000018721A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2000018723A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2001010825A1 (en) 1999-08-05 2001-02-15 Kumiai Chemical Industry Co., Ltd. Carbamate derivatives and agricultural/horticultural bactericides
WO2001040190A1 (en) 1999-11-30 2001-06-07 Pfizer Products Inc. 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
US6747049B2 (en) * 2002-07-03 2004-06-08 Hoffmann-La Roche Inc. Oxazole derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
SK2332004A3 (en) * 2002-08-30 2004-12-01 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
US4064125A (en) 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4122255A (en) 1976-10-29 1978-10-24 E. R. Squibb & Sons, Inc. Substituted amides and sulfonamides containing a heterocyclic group having antiinflammatory activity
US4127606A (en) 1976-10-29 1978-11-28 E. R. Squibb & Sons, Inc. Substituted sulfonamides having antiinflammatory activity
US4151354A (en) 1976-10-29 1979-04-24 E. R. Squibb & Sons, Inc. Substituted amides and sulfonamides having antiinflammatory activity
US4473579A (en) 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
WO1995006626A1 (en) 1993-09-01 1995-03-09 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
WO1995029672A1 (en) 1994-04-29 1995-11-09 Sanofi Winthrop, Inc. HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS
WO1996010559A1 (en) 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5834514A (en) 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
WO1997024328A1 (en) 1995-12-27 1997-07-10 Bayer Aktiengesellschaft 2-amino-heterocycles and therapeutic uses therefor
WO1998004528A2 (en) 1996-07-31 1998-02-05 Bayer Corporation Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
WO1999018066A1 (en) 1997-10-02 1999-04-15 Sankyo Company, Limited Amidocarboxylic acid derivatives
US20040006141A1 (en) 1997-10-02 2004-01-08 Sankyo Company, Ltd Amidocarboxylic acid compounds
WO1999044987A1 (en) 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
US6218426B1 (en) * 1998-03-05 2001-04-17 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents
WO1999067204A1 (en) 1998-06-22 1999-12-29 Astrazeneca Ab Novel compounds
WO2000017166A1 (en) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000017164A1 (en) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000018721A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2000018724A1 (en) 1998-09-25 2000-04-06 Monsanto Company (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY
WO2000018723A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2001010825A1 (en) 1999-08-05 2001-02-15 Kumiai Chemical Industry Co., Ltd. Carbamate derivatives and agricultural/horticultural bactericides
JP2001106666A (ja) 1999-08-05 2001-04-17 Kumiai Chem Ind Co Ltd カーバメート誘導体及び農園芸用殺菌剤
WO2001040190A1 (en) 1999-11-30 2001-06-07 Pfizer Products Inc. 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
US6747049B2 (en) * 2002-07-03 2004-06-08 Hoffmann-La Roche Inc. Oxazole derivatives

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Badimon et al., Journal of Clinical Investigation, 85: 1234-1241 (1990).
Connolly et al., Biochemical and Biophysical Research Communications 223: 42-47 (1996).
Drayna et al., Nature, 327: 632-634 (1987).
Herrera et al., Nature Medicine, vol. 5, No. 12, Dec. 1999, pp. 1383-1389, especially p. 1383. *
Nichols et al., Journal of Lipid Research, 6: 206-210, (1965).
See Herrera et al., Nature Medicine, vol. 5, No. 12, Dec. 1999, pp. 1383-1389, especially p. 1383. *
Therapeutic Bulletin, 20: 1-3 (May 2003).

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807701B2 (en) * 2002-08-30 2010-10-05 Japan Tobacco Inc. Dibenzylamine compounds and pharmaceutical use thereof
US20080146620A1 (en) * 2002-08-30 2008-06-19 Japan Tobacco Inc. Dibenzylamine Compounds and Pharmaceutical Use Thereof
US9782407B2 (en) 2004-12-31 2017-10-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US20110092506A1 (en) * 2006-01-31 2011-04-21 Yoshinori Nakamura Trisubstituted amine compound
US8076364B2 (en) * 2006-01-31 2011-12-13 Mitsubishi Tanabe Pharma Corporation Trisubstituted amine compound
US20090023729A1 (en) * 2006-01-31 2009-01-22 Mitsubishi Tanabe Pharma Corporation Trisubstituted amine compound
US7906517B2 (en) * 2006-01-31 2011-03-15 Mitsubishi Tanabe Pharma Corporation Trisubstituted amine compound
US20090029994A1 (en) * 2006-01-31 2009-01-29 Mitsubishi Tanabe Pharma Corporation Trisubstituted amine compound
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US20070213314A1 (en) * 2006-03-10 2007-09-13 Pfizer Inc Dibenzyl Amine Compounds and Derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US20070213371A1 (en) * 2006-03-10 2007-09-13 Pfizer Inc Dibenzyl Amine Compounds and Derivatives
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
US9000007B2 (en) 2011-09-27 2015-04-07 Dr. Reddy's Laboratories Ltd. 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US12150975B2 (en) 2016-07-27 2024-11-26 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders

Also Published As

Publication number Publication date
BR0306208A (pt) 2004-10-13
PT1533292E (pt) 2007-05-31
EP1533292A1 (en) 2005-05-25
NZ532494A (en) 2006-03-31
ATE353870T1 (de) 2007-03-15
ES2277142T3 (es) 2007-07-01
KR100634195B1 (ko) 2006-10-16
TR200401413T1 (tr) 2005-06-21
SI1533292T1 (sl) 2007-08-31
DE60311821T2 (de) 2007-10-31
CZ2004627A3 (cs) 2004-10-13
US7807701B2 (en) 2010-10-05
ZA200403137B (en) 2005-06-29
CY1106425T1 (el) 2011-10-12
CA2464846A1 (en) 2004-03-11
AU2003261826B2 (en) 2006-02-02
KR20040075908A (ko) 2004-08-30
CN1617850A (zh) 2005-05-18
CA2464846C (en) 2010-04-06
DK1533292T3 (da) 2007-06-04
NO20042584L (no) 2004-06-18
CN1289467C (zh) 2006-12-13
EP1533292A4 (en) 2005-11-02
US20050059810A1 (en) 2005-03-17
AU2003261826A1 (en) 2004-03-19
MXPA04005350A (es) 2004-09-27
HK1077567A1 (en) 2006-04-13
IL161559A (en) 2009-12-24
DE60311821D1 (de) 2007-03-29
SK2332004A3 (en) 2004-12-01
WO2004020393A1 (ja) 2004-03-11
EP1829858A2 (en) 2007-09-05
EP1829858A3 (en) 2007-10-03
EP1533292B1 (en) 2007-02-14
IL161559A0 (en) 2004-09-27
RU2004119546A (ru) 2005-08-10
RU2293078C2 (ru) 2007-02-10
NO328886B1 (no) 2010-06-07
US20080146620A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
US7332514B2 (en) Dibenzylamine compound and medicinal use thereof
TWI481598B (zh) 作為新穎ｎｅｐ抑制劑之經取代胺甲醯基甲基胺基乙酸衍生物
JP5420761B2 (ja) ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
JP5607021B2 (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬としてのアダマンチル誘導体
CN103313708B (zh) 治疗造影剂诱导的肾病的方法
US8247401B2 (en) P2X3 receptor antagonists for treatment of pain
US20130018074A1 (en) New compounds
TW201100393A (en) Substituted aminobutyric derivatives as neprilysin inhibitors
NZ587056A (en) Method for modulating calcium ion-release-activated calcium ion channels
CZ315196A3 (en) Sulfonamide derivatives and pharmaceutical composition containing thereof
AU2007318092A1 (en) Calcium receptor modulating agents
JP5329656B2 (ja) イミダゾリジン誘導体
JP3630676B2 (ja) ジベンジルアミン化合物及びその医薬用途
JP2003221376A (ja) Ｃｅｔｐ活性阻害剤
HK1077567B (en) Dibenzylamine compound and medicinal use thereof
US20250129027A1 (en) Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
KR20120108999A (ko) 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: JAPAN TOBACCO INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAEDA, KIMIYA;NAGAMORI, HIRONOBU;NAKAMURA, HIROSHI;AND OTHERS;REEL/FRAME:015152/0860;SIGNING DATES FROM 20040903 TO 20040906

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
CC Certificate of correction
CC Certificate of correction
ERR Erratum

Free format text: IN THE NOTICE OF CERTIFICATE OF CORRECTION APPEARING IN 20100608 OFFICIAL GAZETTE, DELETE ALL REFERENCE TO PATENT NO. 7332514, ISSUE OF 20100518. THE CERTIFICATE OF CORRECTION IS A DUPLICATE OF CERTIFICATE OF CORRECTION ISSUED ON 20100209

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20200219